Last Updated on November 22, 2023 by The Health Master
Drug Price Regulation
The recent order on Drug Price Regulation by the division bench of the Delhi High Court has sent ripples through the pharmaceutical industry.
In a landmark decision, the court clarified the government’s authority to monitor the pricing of non-scheduled formulations.
This order, issued on November 8, 2023, has far-reaching implications for the future decisions of the drug price regulator, particularly concerning the interpretation of Paragraph 20 of the Drugs (Prices Control) Order, 2013.
Understanding Paragraph 20
1. Background of the Order
The order, delivered by Chief Justice Satish Chandra Sharma and Justice Subramonium Prasad, provides a detailed analysis of various scenarios using hypothetical illustrations.
These scenarios shed light on how Paragraph 20 may be interpreted in different instances.
2. Uniformity in Illustrations
For the sake of uniformity, the order establishes that the Maximum Retail Price (MRP) of a non-scheduled formulation, manufactured by a specific company, is considered Rs. 100 as of February 1, 2014.
3. Permissible Increase in MRP
The order clarifies that a manufacturer can increase the MRP by 10 percent annually, as per Para 20 of the 2013 Drugs (Prices Control) Order.
Scenarios and Implications
4. Scenario 1: Annual Increase
In one scenario, the manufacturer follows a 10% annual increase in MRP. The court rules that penal consequences do not apply as long as the increase remains within the stipulated percentage.
5. Scenario 2: Continuous Annual Increase
Another scenario explores continuous annual increases in MRP. The court emphasizes the manufacturer’s right to round off figures, ensuring no penal consequences even with rounding.
6. Rollback Obligation
The order specifies situations where a manufacturer must roll back the MRP, illustrating the importance of adhering to the prescribed percentage increase.
7. Immediate Reduction Obligation
If a manufacturer fails to adhere to the prescribed increase and increases the MRP immediately, the court mandates an immediate reduction to the permissible limit.
8. Flexibility in MRP
The court acknowledges flexibility in MRP adjustments, as long as the increase stays within the permissible limit and is implemented within the stipulated time frame.
9. Periodic Increase
The order outlines scenarios where a periodic increase in MRP is permissible, emphasizing the need for adherence to the specified percentages.
10. Non-Conforming MRP
In instances where the MRP does not conform to Para 20, the manufacturer is bound by the MRP of the previous twelve months.
11. Deposit Obligations
Manufacturers failing to comply with MRP regulations are obligated to deposit the overcharged amount, highlighting the financial consequences of non-compliance.
12. Reduction and Deposit
The court underscores the manufacturer’s obligation to reduce MRP immediately and deposit the overcharged amount along with interest in specific scenarios.
13. Consequences of Non-Compliance
Non-compliance with MRP regulations can lead to financial liabilities, illustrating the court’s commitment to strict enforcement.
14. Specific Cases
The order delves into specific cases, emphasizing the importance of adhering to Para 20 and the repercussions for non-compliance.
15. Manufacturer’s Entitlement
The court concludes by reiterating that a manufacturer is entitled to increase the MRP based on the permissible limit of the previous twelve months.
Conclusion
The division bench’s order provides a comprehensive interpretation of Paragraph 20 of the Drugs (Prices Control) Order, 2013. Manufacturers are now presented with a clearer understanding of their obligations, ensuring regulatory compliance in drug pricing.
FAQs:
- Is it mandatory for manufacturers to increase the MRP by 10 percent every year?
- No, manufacturers have flexibility, but any increase must adhere to the stipulated percentage.
- What are the consequences of immediate MRP increases beyond the permissible limit?
- Manufacturers are obligated to immediately reduce the MRP and deposit the overcharged amount with interest.
- How does the court address non-compliance with MRP regulations?
- Non-compliance may lead to financial liabilities, including the deposit of overcharged amounts.
- Are manufacturers allowed to round off figures in MRP calculations?
- Yes, the order allows manufacturers to round off figures, ensuring practicality in compliance.
- What is the significance of the court’s emphasis on the previous twelve months’ MRP?
- The previous twelve months’ MRP serves as the basis for permissible increases, emphasizing continuity and adherence.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
Revised Schedule M Guidelines: Drug Recall and Ensuring Pharma Quality
Antibiotic Resistance Crisis in India and Role of Government
USFDA issues warning letter to Cipla for Pithampur plant
CDSCO Guidelines on Drug Recall
Govt Job: For B.Pharm, M.Pharm, MSc at Drugs Control Department
USFDA Approval granted for Ganirelix Acetate injection
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
